Novo Nordisk specializes in the design, production and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- products for treating diabetes (78%): insulin and administration accessories (96.5% of net sales) and oral anti-diabetic products (3.5%);
- hemophilia treatment products (11.4%): mainly injections of protein (NovoSeven);
- growth hormones (7.3%): used fortreatment of growth deficiencies in children (Norditropin and Simplex);
- hormone replacement products (2.8%): used for treatment of the menopause and prevention of osteoporosis;
- other (0.5%).
Net sales break down geographically as follows: Europe (25.3%), North America (43.9%), Japan and Korea (8.5%) and other (22.3%).